No difference in effect between LABA/LAMA and placebo or LABA or LAMA aloneĬOPD = chronic obstructive pulmonary disease LABA = long-acting β-agonist LAMA = long-acting muscarinic antagonist. No difference in effect between LABA/LAMA and LAMA alone More people had improved breathlessness than with placebo or LABA or LAMA aloneįewer people had moderate or severe exacerbations than with placebo or LABA alone More people had improved quality of life than with placebo or LABA or LAMA alone LABA/LAMA drug combination vs placebo, LABA alone, or LAMA alone in COPD Treatments had similar rates of adverse events, including deaths. In people with stable COPD, a LABA/LAMA combination improves quality of life and reduces breathlessness more than placebo, a LABA alone, or a LAMA alone. had similar rates of moderate-to-severe exacerbations, severe exacerbations, death, and serious adverse events.improved quality of life and breathlessness when measured at 3 and 6 months and.had similar quality of life when measured at 6 months and similar rates of severe exacerbations, death, and serious adverse events.Ĭompared with LAMA alone, LABA/LAMA combination:.improved quality of life when measured at 3 months and breathlessness when measured at 3 and 6 months.had similar rates of severe exacerbations, death, and serious adverse events.Ĭompared with LABA alone, LABA/LAMA combination:.reduced moderate-to-severe exacerbations and.improved quality of life and breathlessness when measured at 3 and 6 months.What the researchers foundĬompared with placebo, LABA/LAMA combination: Trials were combined using a type of analysis (“network meta-analysis”) that lets you compare treatments even if they were not compared directly in the individual trials. most people did not know which treatment they were getting during the trials.people were treated for 12 weeks or more and.combination treatment was compared with placebo or a LABA or LAMA drug alone.treatment was a LABA drug (formoterol, indacaterol, olodaterol, salmeterol, or vilanterol) combined with a LAMA drug (aclidinium, glycopyrronium, umeclidinium, or tiotropium).people with asthma, other diseases that affect breathing, or cardiovascular disease were excluded.people had moderate or severe COPD, without a recent exacerbation.The found 23 randomized controlled trials with 27,172 people (average age 61 to 69 years, 52% to 96% men, 26% to 63% current smokers). The researchers did a systematic review, searching for studies up to May 2015. Using a LABA and a LAMA together may control symptoms better than using either drug alone. Bronchodilator drugs, including LABAs and LAMAs, help relax muscles around the airways and make it easier to breath. Symptoms of COPD include difficulty breathing, cough, wheezing, and chest tightness.ĬOPD can be treated, and several types of drugs can help control symptoms. It reduces the flow of air through the lungs and is often associated with smoking. In people with chronic obstructive pulmonary disease (COPD), does a combination of long-acting β-agonist (LABA) and long-acting muscarinic antagonist (LAMA) drugs reduce symptoms and improve quality of life? BackgroundĬOPD is a lung disease with inflammation. Oba Y, Sarva ST, Dias S Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. In people with stable COPD, using LABA and LAMA drugs together rather than alone improves quality of life and reduces breathlessness
0 kommentar(er)
